New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field.
1. New Targeting in the Reversal of Resistant Glioblastomas - p. i 2. Cover - p. i 3. Title Page - p. iii 4. Copyright - p. iv 5. Table of Contents - p. iv 6. Cover Image Insert - p. v 7. Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy” - p. vii 8. About the Series Editor - p. ix 9. Aims and Scope of Volume - p. xi 10. About the Volume Editor - p. xiii 11. Preface - p. xv 12. Contributors - p. xxii 13. Chapter 1 Current status of recurrent glioblastoma therapies - p. 1 14. Chapter 2 Imaging of glioblastoma recurrence - p. 9 15. Chapter 3 Overarching therapeutic challenges and arachidonic acid metabolism as a novel target in glioblastoma - p. 41 16. Chapter 4 Intervention of IL-8-CXCR2 axis to reverse the resistance to GBM therapies - p. 65 17. Chapter 5 Glioma stem cells, plasticity, and potential therapeutic vulnerabilities - p. 83 18. Chapter 6 Targeting glioma stem cell metabolism to enhance therapy responses and minimize resistance - p. 103 19. Chapter 7 Targeting tumor microenvironment-associated cells to reverse therapy resistance - p. 115 20. Chapter 8 The role of convection-enhanced delivery in the treatment of GBM - p. 145 21. Chapter 9 Vectors in gene therapy: Benefit for glioblastoma patients - p. 161 22. Index - p. 177
New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field.
1. New Targeting in the Reversal of Resistant Glioblastomas - p. i 2. Cover - p. i 3. Title Page - p. iii 4. Copyright - p. iv 5. Table of Contents - p. iv 6. Cover Image Insert - p. v 7. Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy” - p. vii 8. About the Series Editor - p. ix 9. Aims and Scope of Volume - p. xi 10. About the Volume Editor - p. xiii 11. Preface - p. xv 12. Contributors - p. xxii 13. Chapter 1 Current status of recurrent glioblastoma therapies - p. 1 14. Chapter 2 Imaging of glioblastoma recurrence - p. 9 15. Chapter 3 Overarching therapeutic challenges and arachidonic acid metabolism as a novel target in glioblastoma - p. 41 16. Chapter 4 Intervention of IL-8-CXCR2 axis to reverse the resistance to GBM therapies - p. 65 17. Chapter 5 Glioma stem cells, plasticity, and potential therapeutic vulnerabilities - p. 83 18. Chapter 6 Targeting glioma stem cell metabolism to enhance therapy responses and minimize resistance - p. 103 19. Chapter 7 Targeting tumor microenvironment-associated cells to reverse therapy resistance - p. 115 20. Chapter 8 The role of convection-enhanced delivery in the treatment of GBM - p. 145 21. Chapter 9 Vectors in gene therapy: Benefit for glioblastoma patients - p. 161 22. Index - p. 177
